Pharmacokinetics, Exposure-Response Relationships, and Immunogenicity in Crohn's Disease Patients With Ustekinumab Secondary Loss of Response Following Ustekinumab IV Re-Induction: Week 16 Results From the POWER Study

被引：0

作者：

Feagan, Brian G. ^{[1
]}

Lee, Scott D. ^{[2
]}

van der Woude, C. Janneke ^{[3
]}

Marin-Jimenez, Ignacio ^{[4
]}

Wolf, Douglas C. ^{[5
]}

Schnoy, Elisabeth ^{[6
]}

Salzberg, Bruce ^{[7
]}

Busse, Christopher ^{[8
]}

Nazar, Maciej ^{[9
]}

Langholff, Wayne ^{[10
]}

Gasink, Christopher ^{[8
]}

Baker, Thomas ^{[10
]}

Godwin, Bridget ^{[8
]}

Adedokun, Omoniyi ^{[10
]}

Schreiber, Stefan ^{[11
]}

机构：

[1] Western Univ, London, ON, Canada

[2] Univ Washington, Seattle, WA USA

[3] Erasmus Univ, Med Ctr, Rotterdam, Netherlands

[4] Hosp Univ Gregorio Maranon, IiSGM, Rotterdam, Zuid Holland, Netherlands

[5] Atlanta Gastroenterol Associates, Atlanta, GA USA

[6] Univ Hosp Augsburg, Augsburg, Germany

[7] IBD Ctr Atlanta, Atlanta Gastroenterol, Atlanta, GA USA

[8] Janssen Sci Affairs LLC, Horsham, PA USA

[9] Janssen Cilag Polska Sp Zoo, Warsaw, Poland

[10] Janssen Res & Dev LLC, Spring House, PA USA

[11] Univ Hosp Schleswig Holstein, Kiel, Germany

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S842

引用

页码：S622 / S622

页数：1

共 50 条

[31] USTEkinumAb Double intravenous loading induction therapY at week 0,4 in patients with Crohn's Disease-results from STEADY study
Chin, A.
Jeffrey, A.
Teh, W. L.
Menon, S.
So, K.
Venugopal, K.
Picardo, S.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 799 - 799
[32] POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY
An, Yoon-Kyo
Lindsay, Niamh
Allan, Natalie
Khoo, Emi
Fernandes, Richard
Amiss, Anna
Hai Pham
Wong, Kam Fai
Ooi, Soong-Yuan
Thin, Lena
Lightowler, Daniel
Connor, Susan J.
Williams, Astrid-Jane
De Cruz, Peter
Suen, Christopher Li Wai
Kariyawasam, Viraj C.
Mitrev, Nikola
Ghaly, Simon
Andrews, Jane M.
Christensen, Britt
Sparrow, Miles
White, Lauren S.
Bryant, Robert V.
Ding, Nik S.
Leong, Rupert
Van Langenberg, Daniel R.
Seltenreich, Hansjoerg
Subramaniam, Kavitha
Radford-Smith, Graham L.
Begun, Jakob
GASTROENTEROLOGY, 2023, 164 (06) : S1108 - S1108
[33] MIRIKIZUMAB PHARMACOKINETICS AND EXPOSURE-RESPONSE IN A PHASE 2 STUDY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE
Chua, Laiyi
Otani, Yuki
Friedrich, Stuart
Durand, Frederick
Zhang, Xin
GASTROENTEROLOGY, 2024, 166 (05) : S822 - S822
[34] Mirikizumab Pharmacokinetics and Exposure-Response in a Phase 2 Study in Patients With Moderately to Severely Active Crohn's Disease
Chua, L.
Otani, Y.
Friedrich, S.
Durand, F.
Zhang, X.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1873 - I1873
[35] BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY
An, Yoon-Kyo
Lindsay, Niamh
Allan, Natalie
Khoo, Emi
Fernandes, Richard
Amiss, Anna
Pham, Hai
Giri, Rabina
Ooi, Soong-Yuan
Thin, Lena
Lightowler, Daniel
Connor, Susan J.
Williams, Astrid-Jane
De Cruz, Peter
Suen, Christopher Li Wai
Kariyawasam, Viraj C.
Mitrev, Nikola
Ghaly, Simon
Andrews, Jane M.
Christensen, Britt
Sparrow, Miles
White, Lauren S.
Bryant, Robert V.
Ding, Nik S.
Leong, Rupert
Van Langenberg, Daniel R.
Seltenreich, Hansjoerg
Subramaniam, Kavitha
Radford-Smith, Graham L.
Begun, Jakob
GASTROENTEROLOGY, 2023, 164 (06) : S657 - S658
[36] Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn's Disease in Phase 2 and 3 Studies
Chua, Laiyi
Otani, Yuki
Friedrich, Stuart
Durand, Frederick
Zhang, Xin
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1056 - S1056
[37] Anti-TNF Re-induction Is as Effective, Simpler, and Cheaper Compared With Dose Interval Shortening for Secondary Loss of Response in Crohn's Disease
Srinivasan, Ashish
Vasudevan, Abhinav
McFarlane, Anne
Sparrow, Miles P.
Gibson, Peter R.
Van Langenberg, Daniel R.
JOURNAL OF CROHNS & COLITIS, 2018, 12 (03): : 280 - 288
[38] Week 48 Efficacy Of Guselkumab And Ustekinumab In Crohn's Disease Based On Prior Response/Exposure To Biologic Therapy: Results From The GALAXI 2 and 3 Phase 3 Studies
Danese, Silvio
Afzali, Anita
Panaccione, Remo
Panes, Julian
Reinisch, Walter
Terry, Natalie A.
Salese, Leonardo
Van Rampelbergh, Rian
Wan, Kitty Y. Y.
Yang, Zijiang
Johanns, Jewel
Zmudzinski, Marcin
Zittan, Eran
Matsuoka, Katsuyoshi
Jairath, Vipul
Rubin, David T.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S741 - S742
[39] Anti-TNF re-induction is as effective, simpler and cheaper compared with dose interval shortening following secondary loss of response in Crohn's disease: a dual centre "real world" study
Srinivasan, A.
Vasudevan, A.
McFarlane, A.
Gibson, P.
Sparrow, M.
van Langenberg, D.
JOURNAL OF CROHNS & COLITIS, 2017, 11 : S45 - S45
[40] CLINICAL AND ENDOSCOPIC RESPONSE TO TREAT-TO-TARGET VERSUS STANDARD OF CARE IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB: WEEK 48 RESULTS OF THE STARDUST TRIAL
Danese, Silvio
Vermeire, Severine
D'Haens, Geert R.
Panes, Julian
Dignass, Axel
Magro, Fernando
Nazar, Maciej
Le Bars, Manuela
Lahaye, Marjolein
Ni, Lioudmila
Lavie, Frederic
Bravata, Ivana
Sloan, Sheldon
Daperno, Marco
Lukas, Milan
Armuzzi, Alessandro
Lowenberg, Mark
Gaya, Daniel
Peyrin-Biroulet, Laurent
GASTROENTEROLOGY, 2021, 160 (06) : S25 - S25

← 1 2 3 4 5 →